RLMD
Relmada Therapeutics, Inc. NASDAQ Listed Jun 20, 2014$7.43
Mkt Cap $544.9M
52w Low $0.34
92.6% of range
52w High $8.00
50d MA $6.53
200d MA $3.69
P/E (TTM)
-5.3x
EV/EBITDA
-3.2x
P/B
3.5x
Debt/Equity
0.0x
ROE
-66.3%
P/FCF
-4.2x
RSI (14)
—
ATR (14)
—
Beta
0.45
50d MA
$6.53
200d MA
$3.69
Avg Volume
1.8M
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
CIK (SEC)
Phone
786 629 1376
2222 Ponce de Leon Boulevard · Coral Gables, FL 33134 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.14 | -0.27 | -92.9% | 6.25 | +4.0% | -2.9% | -3.5% | +4.1% | +9.2% | -2.0% | — |
| Nov 13, 2025 | AMC | -0.04 | -0.30 | -650.0% | 3.88 | -8.8% | +1.8% | +0.5% | +7.6% | -2.1% | +3.3% | — |
| Aug 7, 2025 | AMC | -0.25 | -0.30 | -20.0% | 0.60 | -1.1% | -2.4% | -4.1% | +4.4% | -3.4% | +6.9% | — |
| May 12, 2025 | AMC | -0.31 | -0.58 | -87.1% | 0.40 | -3.0% | -2.1% | +10.3% | -3.9% | +11.5% | +10.4% | — |
| Mar 27, 2025 | AMC | -0.70 | -0.62 | +11.4% | 0.30 | +4.5% | -0.4% | -9.0% | +1.3% | +10.8% | -9.0% | — |
| Nov 7, 2024 | AMC | -0.65 | -0.72 | -10.8% | 0.81 | -0.3% | +0.6% | -0.9% | +1.5% | -2.7% | -1.6% | — |
| Aug 7, 2024 | AMC | -0.83 | -0.59 | +28.9% | 0.81 | -0.9% | -29.0% | +0.0% | +0.0% | +10.4% | +1.2% | — |
| May 8, 2024 | AMC | -0.90 | -0.72 | +20.0% | 0.96 | +1.8% | -0.8% | -7.1% | +0.0% | +3.1% | -4.4% | — |
| Mar 19, 2024 | AMC | -0.88 | -0.84 | +4.5% | 1.34 | +3.0% | -17.2% | +5.4% | +4.3% | +0.8% | -4.9% | — |
| Nov 8, 2023 | AMC | -0.95 | -0.73 | +23.2% | 0.75 | +0.3% | -0.3% | -3.0% | -2.8% | +4.6% | +2.7% | — |
| Aug 8, 2023 | AMC | -0.92 | -0.84 | +8.7% | 0.64 | +0.4% | +7.1% | +5.1% | +8.4% | +2.6% | +7.2% | — |
| May 11, 2023 | AMC | -0.88 | -0.87 | +1.1% | 0.79 | -2.2% | -6.3% | +4.0% | -5.5% | +6.2% | +0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | Mizuho | Maintains | Outperform → Outperform | — | $6.25 | $6.50 | +4.0% | -2.9% | -3.5% | +4.1% | +9.2% | -2.0% |
| Jan 23 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $3.96 | $4.31 | +8.8% | -1.5% | +1.8% | +3.3% | -3.7% | -1.0% |
| Nov 19 | Mizuho | Upgrade | Neutral → Outperform | — | $4.27 | $4.50 | +5.4% | -2.1% | +3.3% | -1.2% | +0.7% | -0.9% |
| Dec 5 | Mizuho | Downgrade | Outperform → Neutral | — | $0.63 | $0.64 | +1.6% | -28.6% | +1.7% | +5.1% | -2.3% | -11.1% |
| Dec 4 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $0.69 | $0.69 | +0.4% | -9.0% | -28.6% | +1.7% | +5.1% | -2.3% |
| Jun 5 | Goldman Sachs | Downgrade | Neutral → Sell | — | $0.74 | $0.72 | -2.7% | +0.3% | +2.7% | -3.0% | +5.8% | -2.6% |
| Jun 15 | Mizuho | Maintains | Buy → Buy | — | $0.64 | $0.64 | +0.0% | -0.8% | +2.0% | +10.0% | -4.5% | -6.2% |
| Jan 23 | SVB Leerink | Maintains | Outperform → Outperform | — | $1.19 | $1.18 | -0.8% | -6.7% | -4.5% | +3.8% | -4.5% | -1.9% |
| Oct 14 | Guggenheim | Downgrade | Buy → Neutral | — | $1.62 | $1.57 | -3.1% | -4.3% | +9.7% | +11.8% | -2.6% | +3.8% |
| Oct 14 | Goldman Sachs | Downgrade | Buy → Neutral | — | $1.62 | $1.57 | -3.1% | -4.3% | +9.7% | +11.8% | -2.6% | +3.8% |
| Oct 13 | Oppenheimer | Downgrade | Outperform → Perform | — | $6.34 | $1.67 | -73.7% | -74.4% | -4.3% | +9.7% | +11.8% | -2.6% |
| Sep 23 | Goldman Sachs | Maintains | Buy → Buy | — | $6.11 | $5.99 | -2.0% | +4.4% | -0.3% | +4.6% | +4.5% | +4.2% |
| Sep 6 | Guggenheim | Maintains | Buy → Buy | — | $5.94 | $6.04 | +1.7% | +4.0% | -2.1% | +5.8% | -0.3% | +1.1% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.25 | $4.13 | -2.8% | -5.9% | -1.0% | -6.1% | -0.5% | +7.0% |
| Mar 24 | Goldman Sachs | Maintains | Buy → Buy | — | $4.67 | $4.68 | +0.2% | +7.5% | +2.6% | +0.0% | +0.0% | +1.2% |
| Dec 20 | SVB Leerink | Maintains | Outperform → Outperform | — | $3.81 | $3.80 | -0.3% | +7.9% | +1.9% | +0.7% | +5.5% | -2.2% |
| Nov 18 | Mizuho | Maintains | Buy → Buy | — | $4.29 | $4.52 | +5.4% | -1.9% | -3.1% | -4.9% | -2.1% | +2.9% |
| Nov 25 | Goldman Sachs | Maintains | Buy → Buy | — | $6.98 | $6.96 | -0.3% | +0.0% | +3.2% | -1.2% | -1.8% | -1.7% |
| Nov 25 | Jefferies | Maintains | Buy → Buy | — | $6.98 | $6.96 | -0.3% | +0.0% | +3.2% | -1.2% | -1.8% | -1.7% |
| Nov 25 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $6.98 | $6.96 | -0.3% | +0.0% | +3.2% | -1.2% | -1.8% | -1.7% |
| Oct 28 | Goldman Sachs | Downgrade | Buy → Neutral | — | $6.61 | $6.16 | -6.8% | -4.2% | -1.6% | -0.6% | -3.4% | +5.2% |
| May 4 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $7.88 | $8.50 | +7.9% | +2.0% | +4.0% | -1.9% | -1.2% | +2.1% |
| Apr 21 | Goldman Sachs | Maintains | Buy → Buy | — | $7.08 | $7.32 | +3.4% | -5.9% | +4.7% | +0.6% | +2.9% | +4.4% |
| Jan 27 | Jefferies | Maintains | Buy → Buy | — | $8.66 | $8.41 | -2.9% | +2.9% | +5.4% | -1.6% | +1.4% | -5.3% |
| Dec 16 | Guggenheim | Maintains | Buy → Buy | — | $6.83 | $8.01 | +17.3% | +17.1% | +4.9% | +3.3% | +0.2% | -1.2% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Trellis Research Limited (RLMD) disclosed material non-public information under Regulation FD, suggesting a significant company development or guidance update that could immediately impact stock valuation and trading activity.
Mar 20
8-K · 8.01
!! High
Relmada Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Relmada's NDV-01 achieved a 76% complete response rate in Phase 2 bladder cancer trials at 12 months, with favorable safety, supporting advancement toward potential commercialization.
Mar 9
Data updated apr 26, 2026 11:02pm
· Source: massive.com